RCELAVITA Medical, Inc.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is th…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. During a key opinion leader webinar, the company | ||
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets. Presid | ||
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference. Vance, who has been CEO for about 10 months after previously serving | ||
 AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript Revenue exceeded $21.7 million with guidance raised to $86M–$89M for full year. | ||
 AVITA Medical, Inc. Q2 2026 Earnings Call Summary Moby summary of AVITA Medical, Inc.'s Q2 2026 earnings call | ||
 Avita Medical Shares Surge After Record Second-Quarter Performance Avita Medical (NASDAQ:RCEL) shares jumped 21. 7% in premarket trading after the regenerative medicine company delivered record second-quarter financial results that exceeded analyst expectations on both revenue and earnings. | ||
 Avita Medical Q2 Earnings Call Highlights Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results. President and Chief Executive Officer Cary Vance said the company’s U.S. RE | ||
AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ... AVITA Medical Inc (AVHHL) raises full-year 2026 revenue guidance to $86-$89 million and expects cash flow breakeven by Q4. | ||
 AVITA Medical (RCEL) Stock Sees Fair Value Lift As Analysts Back RECELL Momentum AVITA Medical’s fair value estimate has been reset from US$6.98 to US$9.00 per share, giving investors a fresh reference point for how analysts are framing the stock today. Behind this change, recent commentary highlights optimism around RECELL adoption, revenue momentum, and cash flexibility, while also flagging that execution against guidance and liquidity remain key watchpoints. As you read on, you will see how these shifting pieces of the AVITA Medical story fit together and what to watch... | ||